Vera Therapeutics logo
Vera Therapeutics
VERA | NASDAQ
Chart Builder DCF Calculator
$26.97
-$1.13 (-4.02%)
At close: Nov 16, 2026, 4:00 PM ET
$26.85
-$0.12 (-0.44%)
After-hours: Nov 16, 2026, 7:30 PM ET

Vera Therapeutics Company Profile

Company profile explained

Company Profile

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.

Key Executives

Name Position
Marshall Fordyce Founder, President, Chief Executive Officer & Director
Jane Wright-Mitchell Chief Legal Officer & Secretary
Sean Grant Chief Financial Officer
David L. Johnson Chief Opearating Officer
Debra Charlesworth Vice President of Corporate Communications
Emma Haywood Vice President of Marketing
Joseph R. Young Senior Vice President of Finance & Chief Accounting Officer
Robert Brenner Chief Medical Officer
S. Sandra Park Senior Vice President of Legal, Healthcare,Commercial Law, Compliance & Operations
Tom Doan Executive Vice President of Development Operations

Latest SEC Filings

Date Type Title
Sep 17, 2026 4 Filing
Sep 15, 2026 8-K Current Report
Sep 14, 2026 4 Filing
Sep 04, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 12, 2026 4/A [Amend] Filing
Aug 12, 2026 4/A [Amend] Filing
Aug 12, 2026 4/A [Amend] Filing
Aug 10, 2026 10-Q Quarterly Report
Aug 10, 2026 8-K Current Report
View All SEC Filings ➞
Vera Therapeutics
Vera Therapeutics logo
Country United States
IPO Date May 14, 2021
Industry Biotechnology
Sector Healthcare
Employees 361
CEO Marshall Fordyce

Contact Details

2000 Sierra Point Parkway Brisbane, California 94005 United States

Stock Details

Ticker Symbol VERA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001831828
CUSIP Number 92337R101
ISIN Number US92337R1014
SIC Code 2834

Recent News

More News ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.